arrow_back Back to App

Nullifying mifepristone access changes and prohibiting federal funding.

This bill aims to reverse modifications made by the Food and Drug Administration (FDA) regarding the use of mifepristone. This could mean that access to this medication would revert to previous regulations. Additionally, the bill prohibits the use of federal funds to implement or enforce new, similar rules concerning mifepristone.
Key points
Nullifies FDA modifications from January 3, 2023, concerning mifepristone, potentially impacting its availability.
Prohibits federal funding for establishing, implementing, or enforcing new, similar mifepristone regulations.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_5850
Sponsor: Rep. Mann, Tracey [R-KS-1]
Process start date: 2023-09-29
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_5850.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-09-29.

What are the main provisions?

Key points include:

  • Nullifies FDA modifications from January 3, 2023, concerning mifepristone, potentially impacting its availability.
  • Prohibits federal funding for establishing, implementing, or enforcing new, similar mifepristone regulations.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Mann, Tracey [R-KS-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health